![]() |
|
|
Vol. 296, Issue 1, 124-131, January 2001
Institut National de la Santé et de la Recherche
Médicale U26, Hôpital Fernand Widal, Paris, France (C.R.,
M.S., J.-M.L., J.-M.S.); Synt:em, Parc Scientifique Georges Besse,
Nîmes, France (P.C., J.T.); and Center de Biochimie
Structurale, Faculté de Pharmacie, Montpellier I, France (A.C.,
B.C.)
Doxorubicin delivery to the brain is often restricted because of the
poor transport of this therapeutic molecule through the blood-brain
barrier (BBB). To overcome this problem, we have recently developed a
technology, Pep:trans, based on short natural-derived peptides that are
able to cross efficiently the BBB without compromising its integrity.
In this study, we have used the in situ mouse brain perfusion method to
evaluate the brain uptake of free and vectorized doxorubicin.
Doxorubicin was coupled covalently to small peptide vectors:
L-SynB1 (18 amino acids), L-SynB3 (10 amino
acids), and its enantio form D-SynB3. We first confirmed
the very low brain uptake of free radiolabeled doxorubicin, which is
most likely due to the efflux activity of the P-glycoprotein at
the level of the BBB. Vectorization with either L-SynB1,
L-SynB3, or D-SynB3 significantly increased the
brain uptake of doxorubicin (about 30-fold). We also investigated the
mechanism of transport of vectorized doxorubicin. We show that
vectorized doxorubicin uses a saturable transport mechanism to cross
the BBB. The effect of poly(L-lysine) and protamine,
endocytosis inhibitors, on the transport across the brain was also
investigated. Both inhibitors reduced the brain uptake of vectorized
doxorubicin in a dose-dependent manner. These studies indicate that the
transport of vectorized doxorubicin appears to occur via an
adsorptive-mediated endocytosis.
This article has been cited by other articles:
![]() |
E. Dupont, A. Prochiantz, and A. Joliot Identification of a Signal Peptide for Unconventional Secretion J. Biol. Chem., March 23, 2007; 282(12): 8994 - 9000. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Temsamani, C. Bonnafous, C. Rousselle, Y. Fraisse, P. Clair, L.-A. Granier, A. R. Rees, M. Kaczorek, and J.-M. Scherrmann Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 712 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Monnaert, D. Betbeder, L. Fenart, H. Bricout, A. M. Lenfant, C. Landry, R. Cecchelli, E. Monflier, and S. Tilloy Effects of {gamma}- and Hydroxypropyl-{gamma}-cyclodextrins on the Transport of Doxorubicin across an in Vitro Model of Blood-Brain Barrier J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1115 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Drin, S. Cottin, E. Blanc, A. R. Rees, and J. Temsamani Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides J. Biol. Chem., August 15, 2003; 278(33): 31192 - 31201. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rousselle, P. Clair, M. Smirnova, Y. Kolesnikov, G. W. Pasternak, S. Gac-Breton, A. R. Rees, J.-M. Scherrmann, and J. Temsamani Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 371 - 376. [Abstract] [Full Text] [PDF] |
||||